Sigyn Therapeutics™ Announces Appointment of Annette Marleau, Ph.D. as Chief Scientific Officer
11 avr. 2023 08h30 HE
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, April 11, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTCQB: SIGY) (“Sigyn Therapeutics” or the “Company”), a development-stage company focused on the...
Sigyn Therapeutics Announces Third Quarter 2022 Financial Results
15 nov. 2022 07h30 HE
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage company focused on creating therapeutic...
Sigyn Therapeutics™ Announces Cancer-Related Patent Submission Entitled: “System and Methods to Enhance Chemotherapy Delivery and Reduce Toxicity”
06 oct. 2022 08h30 HE
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, Oct. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage company focused on creating therapeutic...
Sigyn Therapeutics™ Strengthens Board of Directors With the Appointments of Richa Nand, Jim Dorst and Christopher Wetzel
04 oct. 2022 09h00 HE
|
Sigyn Therapeutics, Inc.
- Independent Directors Bring Expertise in Intellectual Property, Finance, Healthcare Delivery, and More - SAN DIEGO, CA, Oct. 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics,...
Sigyn Therapeutics Announces First-In-Human Clinical Strategy to Address Inflammation and Endotoxemia in End-Stage Renal Disease Patients
14 sept. 2022 09h00 HE
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, Sept. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTCQB: SIGY), a development-stage company focused on the creation of therapeutic solutions that address...
Sigyn Therapeutics to Commence Trading on the OTCQB® Venture Exchange
03 août 2022 06h30 HE
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, Aug. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTCQB: SIGY), a development-stage medical technology company focused on addressing unmet needs in global...
Sigyn Therapeutics Appoints Alexander S. Yevzlin, MD, FASN to Its Scientific Advisory Board
09 mars 2022 09h00 HE
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, March 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTC Markets: “SIGY”), a medical technology company focused on the treatment of pathogen-associated...
Sigyn Therapeutics Featured on National Public Radio: “Addressing the Cytokine Storm”
30 août 2021 07h30 HE
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, Aug. 30, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTC Markets: SIGY), a medical technology company focused on the treatment of life-threatening...
Sigyn Therapeutics CEO Note: A Treatment Candidate to Address Bloodstream Pathogens, Deadly Toxins and Inflammatory Disease Targets
10 août 2021 06h30 HE
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, Aug. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTC Markets: SIGY), a medical technology company focused on the treatment of sepsis and other...
Sigyn Therapeutics Announces Rapid Elimination of Hepatic Toxins from Human Blood Plasma
15 juil. 2021 07h30 HE
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, July 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), a medical technology company focused on the treatment of sepsis and other...